Cargando…

Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study

Treating severe COVID-19 patients and controlling the spread of SARS-CoV-2 are concurrently important in mitigating the pandemic. Classically, antiviral drugs are primarily developed for treating hospitalized COVID-19 patients with severe diseases to reduce morbidity and/or mortality, which have lim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Qinyue, Bao, Chunbing, Ji, Yunpeng, Li, Pengfei, Ma, Zhongren, Wang, Xinwei, Meng, Qingchun, Pan, Qiuwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071263/ https://www.ncbi.nlm.nih.gov/pubmed/37016035 http://dx.doi.org/10.1038/s41598-023-32619-z

Ejemplares similares

Mathematical modelling and projecting the second wave of COVID-19 pandemic in Europe
por: Zheng, Qinyue, et al.
Publicado: (2021)

A multi‐regional, hierarchical‐tier mathematical model of the spread and control of COVID‐19 epidemics from epicentre to adjacent regions
por: Zheng, Qinyue, et al.
Publicado: (2021)

Distinct effectiveness in containing COVID-19 epidemic: Comparative analysis of two cities in China by mathematical modeling
por: Ji, Yunpeng, et al.
Publicado: (2021)

Projecting the global spread of the 2022 monkeypox outbreak considering population mobility
por: Zheng, Qinyue, et al.
Publicado: (2022)

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
por: Li, Pengfei, et al.
Publicado: (2022)

Estimating the burden and modeling mitigation strategies of pork-related hepatitis E virus foodborne transmission in representative European countries
por: Ji, Yunpeng, et al.
Publicado: (2021)

Projecting the impact of testing and vaccination on the transmission dynamics of the 2022 monkeypox outbreak in the USA
por: Zheng, Qinyue, et al.
Publicado: (2022)

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses
por: Wang, Yining, et al.
Publicado: (2021)

Disparities in transmission dynamics of the 2022 mpox outbreaks between Europe and Americas
por: Zheng, Qinyue, et al.
Publicado: (2023)

Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
por: Rosenke, Kyle, et al.
Publicado: (2022)

Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir
por: Liu, Yayun, et al.
Publicado: (2022)

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Estimating the global prevalence of hepatitis E virus in swine and pork products
por: Li, Pengfei, et al.
Publicado: (2021)

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
por: Vangeel, Laura, et al.
Publicado: (2022)

Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial
por: Zou, Rongrong, et al.
Publicado: (2022)

Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?
por: Ma, Zhongren, et al.
Publicado: (2020)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
por: Weil, Clara, et al.
Publicado: (2023)

Genomic characteristics and viral load dynamics of a SARS-CoV-2 Omicron BA.2.2 variant from a hospitalized patient treated with molnupiravir
por: Chan, Wai Sing, et al.
Publicado: (2022)

Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial
por: Liu, Yayun, et al.
Publicado: (2023)

Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model
por: Rosenke, Kyle, et al.
Publicado: (2022)

Potential association between COVID-19 mortality and health-care resource availability
por: Ji, Yunpeng, et al.
Publicado: (2020)

Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
por: Suzuki, Yasuhito, et al.
Publicado: (2022)

Immunosuppressants exert differential effects on pan‐coronavirus infection and distinct combinatory antiviral activity with molnupiravir and nirmatrelvir
por: Wang, Yining, et al.
Publicado: (2023)

Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses
por: Ma, Zhongren, et al.
Publicado: (2020)

Unique challenges to control the spread of COVID-19 in the Middle East
por: Baloch, Zulqarnain, et al.
Publicado: (2020)

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
por: Teli, Divya, et al.
Publicado: (2023)

Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis
por: Huang, Chienhsiu, et al.
Publicado: (2023)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Systematically comparing COVID-19 with the 2009 influenza pandemic for hospitalized patients
por: Li, Pengfei, et al.
Publicado: (2021)

NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19
Publicado: (2021)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study
por: Wai, Abraham Ka-chung, et al.
Publicado: (2023)

Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses
por: Ma, Zhongren, et al.
Publicado: (2020)

Comorbidity Burden in Patients with Covid-19 Treated with Molnupiravir in the United States
por: Prajapati, Girish, et al.
Publicado: (2022)

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
por: Cegolon, Luca, et al.
Publicado: (2023)

The impact of COVID-19 pandemic outbreak on education and mental health of Chinese children aged 7–15 years: an online survey
por: Ma, Zhongren, et al.
Publicado: (2021)

Mathematical modeling for Delta and Omicron variant of SARS-CoV-2 transmission dynamics in Greece
por: Liossi, Sofia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2p398rb2n1grg13eocjjihf4vo